Cargando…

Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Chronic Obstructive Pulmonary Disease — Hebei Province, China, September−December, 2019

WHAT IS ALREADY KNOWN ON THIS TOPIC? The global burden of chronic obstructive pulmonary disease (COPD) is serious. Pneumococcal infection is associated with acute exacerbations of COPD (AECOPD). The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for COPD patients to decrease A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yan, Ma, Ying, An, Zhijie, Yue, Chenyan, Wang, Yamin, Wang, Liye, Liu, Yunqiu, Yuan, Xiaodong, Zhang, Shuping, Ye, Qiang, Li, Hong, Li, Keli, Yin, Zundong, Wang, Huaqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2021
Materias:	Preplanned Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393071/ https://www.ncbi.nlm.nih.gov/pubmed/34594878 http://dx.doi.org/10.46234/ccdcw2021.089

Ejemplares similares

Impact of Influenza and Pneumococcal Polysaccharide Vaccination on Economic Burden from Acute Exacerbations of Chronic Obstructive Pulmonary Disease — Hebei Province, China, November 2018 to November 2020
por: Li, Yan, et al.
Publicado: (2023)

Coverage of 13-Valent Pneumococcal Conjugate Vaccine Among Children 0–15 Months of Age — 9 Provinces, China, 2019–2021
por: Liu, Lijun, et al.
Publicado: (2023)

Survey on Immunization Services for Children with Medical Conditions — China, 2022
por: Huang, Yong, et al.
Publicado: (2023)

Association of COVID-19 Vaccination and Clinical Severity of Patients Infected with Delta or Omicron Variants — China, May 21, 2021–February 28, 2022
por: Li, Mingshuang, et al.
Publicado: (2022)

Temperature-Modified Acute Effects of Ozone on Human Mortality — Beijing Municipality, Tianjin Municipality, Hebei Province, and Surrounding Areas, China, 2013–2018
por: Chen, Chen, et al.
Publicado: (2021)

Progress Toward Measles Elimination — China, January 2013-June 2019
por: Ma, Chao, et al.
Publicado: (2019)

The Associated Factors of SARS-CoV-2 Reinfection by Omicron Variant — Guangdong Province, China, December 2022 to January 2023
por: Cai, Chunsheng, et al.
Publicado: (2023)

Medical Consultations Option and Influencing Factors for SARS-CoV-2 Infected Individuals — Beijing Municipality, China, December 2022
por: Li, Mingyue, et al.
Publicado: (2023)

The Long-Term Impacts of COVID-19 on Physical and Psychological Health — Beijing Municipality, China, December 2022–April 2023
por: Tian, Tian, et al.
Publicado: (2023)

Cross-Sectional Online Survey on Depression and Anxiety Among the Population Infected or Non-Infected with COVID-19 — China, December 2022
por: Qin, Tingting, et al.
Publicado: (2023)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021
por: Wu, Dan, et al.
Publicado: (2022)

The Infection of Healthcare Workers and the Reinfection of Patients by Omicron Variant — Jiangsu Province, China, December 2022 to January 2023
por: Zhang, Chuanmeng, et al.
Publicado: (2023)

Independent and Interactive Effects of Environmental Conditions on Aerosolized Surrogate SARS-CoV-2 — Beijing, China, June to September 2020
por: Mao, Yixin, et al.
Publicado: (2022)

Willingness of Caregivers to Have Their Children Vaccinated with Pneumococcal Vaccines in the Context of an Innovative Immunization Strategy — Weifang City, Shandong Province, 2021
por: Yang, Yuan, et al.
Publicado: (2022)

Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
por: Haggenburg, Sabine, et al.
Publicado: (2023)

Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations
por: Wang, Yang, et al.
Publicado: (2017)

Effectiveness of DTaP Against Pertussis in ≤2-Year-Old Children — Linyi Prefecture, Shandong Province, China, 2017–2019
por: Zhu, Pinpin, et al.
Publicado: (2023)

A Comparison of Clinical Characteristics of Infections with SARS-CoV-2 Omicron Subvariants BF.7.14 and BA.5.2.48 — China, October–December 2022
por: Huo, Da, et al.
Publicado: (2023)

Effectiveness of COVID-19 Vaccination Against SARS-CoV-2 Omicron Variant Infection and Symptoms — China, December 2022–February 2023
por: Fu, Di, et al.
Publicado: (2023)

Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly
por: Seo, Yu Bin, et al.
Publicado: (2017)

Monitoring the Effective Sterilization of Low-Temperature Hydrogen Peroxide Gas Plasma Sterilizers in 58 Hospitals — 22 PLADs, China, June 2015–December 2019
por: Wang, Jiaqi, et al.
Publicado: (2021)

An Analysis of Life-Year Lost Due to COVID-19 — 34 Countries, December 2019–March 2021
por: Jiang, Shan, et al.
Publicado: (2022)

Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly
por: Kuo, Chia-Sheng, et al.
Publicado: (2016)

A Review of the Impact of Pneumococcal Polysaccharide Conjugate Vaccine (7-valent) on Pneumococcal Meningitis
por: Tin Tin Htar , Myint, et al.
Publicado: (2013)

The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities
por: Li, Yan, et al.
Publicado: (2021)

Quantitative Analysis on NCDs Prevention and Control Policies Based on the Perspective of Policy Instruments — China, 1990–2020
por: Zhao, Yanfang, et al.
Publicado: (2022)

Outbreaks of Acute Respiratory Disease Associated with Human Adenovirus Infection in Closed Camps, China, December 2011–March 2014
por: Du, Juan, et al.
Publicado: (2021)

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
por: Garcia Garrido, Hannah M., et al.
Publicado: (2022)

Multiple Center Research on Relationship Between Screening Quality and Detection of Cervical Cancer — Six Provinces, China, June–December 2021
por: Zhang, Xiaosong, et al.
Publicado: (2023)

P1523: IMMUNOGENICITY OF THE 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINE FOLLOWED BY THE 23-VALENT POLYSACCHARIDE VACCINE IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Haggenburg, Sabine, et al.
Publicado: (2023)

Attitudes Regarding Influenza Vaccination Among Public Health Workers during COVID-19 Pandemic — China, September 2022
por: Yi, Heya, et al.
Publicado: (2023)

Evaluation of China Healthy Lifestyle for All Interventions Based on RE-AIM Framework — China, 2007–2020
por: Wu, Fugui, et al.
Publicado: (2022)

Effect of 23-valent pneumococcal polysaccharide vaccine on medical expenses in Japan
por: Satomura, Kazunari, et al.
Publicado: (2014)

Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae
por: Turner, Allison E.B., et al.
Publicado: (2017)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
por: Malene B, Mikkelsen, et al.
Publicado: (2023)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
por: Ngamprasertchai, Thundon, et al.
Publicado: (2023)

Association Between COVID-19 Vaccination Coverage and Case Fatality Ratio: a Comparative Study — Hong Kong SAR, China and Singapore, December 2021–March 2022
por: He, Guanhao, et al.
Publicado: (2022)

A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV
por: Wilck, Marissa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fe5741vo31a25g77shmq2i5aic